[New obesity and metabolic syndrome treatment: rimonabant].
CBI endocannabinoid system receptors localized in the hypothalamus and the nucleus accumbens are known to regulate hunger. Hyperstimulation of the CBI receptors lead to an increase of food intake, but also to an increase of lipogenesis, decrease of adiponectin and increase of insulin resistance. Rimonabant is the first CBI central and peripheral blocker, tested in international trials (RIO-lipids, RIO-Europe and RIO-North America). Significant results on weight reduction, increased adiponectin and improved metabolic syndrome have been demonstrated. Rimonabant is a new pharmacological therapy and very interesting for tackling obesity and metabolic syndrome.
Makoundou
V
V
Service d'enseignement thérapeutique pour maladies chroniques, Département de médecine communautaire HUG, 121 I Geneve 14.
Golay
A
A
D004435:Eating; D006801:Humans; D007333:Insulin Resistance; D050356:Lipid Metabolism; D024821:Metabolic Syndrome / Q000188:drug therapy*; D009765:Obesity / Q000188:drug therapy*; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use*; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use*; D043882:Receptors, Cannabinoid / Q000187:drug effects / Q000502:physiology; D000077285:Rimonabant
D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D000077285:Rimonabant